Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16449781 | 1.00 | MAPT (0.44) | MAPTHSP90AA1GPR55HIF1ACYP3A4 | |
| SCHEMBL15745582 | 1.00 | MAPT (0.44) | MAPTHSP90AA1GPR55HIF1ACYP3A4 | |
| SCHEMBL13305755 | 0.86 | CYP2C19 (0.42) | MAPTHIF1AADRA2AADRA2CLMNA | |
| SCHEMBL13351981 | 0.81 | RIPK1 (0.50) | MAPTLMNA | |
| SCHEMBL25530546 | 0.80 | KIF11 (0.43) | MAPTLMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL8462436 | 0.78 | SRC (0.56) | MAPTHSP90AA1GPR55HIF1ACYP3A4 | |
| SCHEMBL409758 | 0.78 | POLB (0.50) | MAPTHSP90AA1GPR55HIF1ACYP3A4 | |
| SCHEMBL7762850 | 0.78 | GRM8 (0.44) | CYP3A4LMNAL3MBTL1 | |
| SCHEMBL8279099 | 0.78 | LMNA (0.48) | HIF1AADRA2AADRA2CLMNAKDM4E | |
| SCHEMBL11985509 | 0.78 | LMNA (0.48) | HIF1AADRA2AADRA2CLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286092-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL, LTD. (BM) | 2010-11-11 | — | — | US | disclosed |
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | MAPT 3009/4885HSP90AA1 1868/4885GPR55 2694/4885 |
| US-20100286092-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | MAPT 3009/4885HSP90AA1 1868/4885GPR55 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.